First-line panitumumab plus FOLFOX4 or FOLFIRI in colorectal cancer with multiple or unresectable liver metastases: A randomised, phase II trial (PLANET-TTD)

Carrato Alfredo; Abad Albert; Massuti Bartomeu; Gravalos Cristina; Escudero Pilar; Longo-Munoz Federico; Manzano Jose-Luis; Gomez Auxiliadora; Safont Maria Jose; Gallego Javier; Garcia-Paredes Beatriz; Pericay Carles; Duenas Rosario; Rivera Fernando; Losa Ferran; Valladares-Ayerbes Manuel; Gonalez Encarnacion; Aranda Enrique

首页> 外文期刊>European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) >First-line panitumumab plus FOLFOX4 or FOLFIRI in colorectal cancer with multiple or unresectable liver metastases: A randomised, phase II trial (PLANET-TTD)

【24h】

First-line panitumumab plus FOLFOX4 or FOLFIRI in colorectal cancer with multiple or unresectable liver metastases: A randomised, phase II trial (PLANET-TTD)

机译：一线Panitumumab加folfox4或Folfiri在结肠直肠癌中，具有多种或不可切除的肝转移：A随机，第二期试验（Planet-TTD）

获取原文

获取原文并翻译 | 示例

获取外文期刊封面目录资料

开具论文收录证明 >>

文献代查 >>

文献数据库（团队版） >>

页面导航

摘要
著录项
引文网络
相似文献
相关主题

摘要

Background: In first-line wild-type (WT)-Kirsten rat sarcoma viral oncogene homologue (KRAS) metastatic colorectal cancer (mCRC), panitumumab (Pmab) improves outcomes when added to FOLFOX [folinic acid, 5-fluorouracil, and oxaliplatin] or FOLFIRI [folinic acid, 5-fluorouracil, and irinotecan]. However no trial has directly compared these combinations.

机译：背景：在一线野生型（WT） - kirsten大鼠肉瘤病毒癌基因同源物（Kras）转移性结肠直肠癌（McRC），Panitumumab（Pmab）加入到Folfox [叶酸，5-氟尿嘧啶和oxaliplatin时]改善结果或folfiri [叶酸，5-氟尿嘧啶和伊立替康]。但是，没有试验直接比较了这些组合。

著录项

来源
《European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)》 |2017年第2017期|共12页
作者
Carrato Alfredo; Abad Albert; Massuti Bartomeu; Gravalos Cristina; Escudero Pilar; Longo-Munoz Federico; Manzano Jose-Luis; Gomez Auxiliadora; Safont Maria Jose; Gallego Javier; Garcia-Paredes Beatriz; Pericay Carles; Duenas Rosario; Rivera Fernando; Losa Ferran; Valladares-Ayerbes Manuel; Gonalez Encarnacion; Aranda Enrique;
展开▼
作者单位

Alcala Univ Ramon y Cajal Univ Hosp Ramon y Cajal Inst Hlth Res IRYCIS CIBERONC Carretera;

Germans Trias &

Pujol Hosp ICO Carretera Canyet S-N ES-08916 Badalona Spain;

Alicante Gen Hosp Pintor Baeza 11 ES-03010 Alicante Spain;

Doce de Octubre Hosp Ave Cordoba S-N ES-28041 Madrid Spain;

Clin Lozano Blesa Hosp Ave San Juan Bosco 15 ES-50009 Zaragoza Spain;

Alcala Univ Ramon y Cajal Univ Hosp Ramon y Cajal Inst Hlth Res IRYCIS CIBERONC Carretera;

Germans Trias &

Pujol Hosp ICO Carretera Canyet S-N ES-08916 Badalona Spain;

IMIBIC Maimonides Inst Biomed Res Zaragoza Spain;

Valencia Gen Hosp Avenida Tres Cruces 2 ES-46014 Valencia Spain;

Elche Gen Univ Hosp Cami Almazara 11 ES-03203 Alicante Spain;

San Carlos Hosp Calle Prof Martin Lagos S-N ES-28040 Madrid Spain;

Corp Sanitaria Parc Tauli Sabadell Hosp Parc Tauli 1 ES-08208 Sabadell Spain;

Jaen Hosp Complex Ave Ejercito Espanol 10 ES-23007 Jaen Spain;

Marques de Valdecilla Hosp Ave Valdecilla S-N ES-39008 Santander Spain;

LHospitalet Gen Hosp Ave Josep Molins 29 ES-08906 Lhospitalet De Llobregat Spain;

A Coruna Univ Hosp Complex As Xubias 84 ES-15006 La Coruna Spain;

Virgen de las Nieves Hosp Ave Fuerzas Armadas 2 ES-18014 Granada Spain;

IMIBIC Maimonides Inst Biomed Res Zaragoza Spain;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词
Panitumumab; FOLFOX; FOLFIRI; Metastatic colorectal cancer; First-line; Liver-limited disease; Resection;

机译：panitumumab;folfox;folfiri;转移性结直肠癌;一线;肝脏有限的疾病;切除;

相似文献

外文文献
中文文献
专利

1. First-line panitumumab plus FOLFOX4 or FOLFIRI in colorectal cancer with multiple or unresectable liver metastases: A randomised, phase II trial (PLANET-TTD) [J] . Carrato Alfredo, Abad Albert, Massuti Bartomeu, European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2017,第期

机译：一线Panitumumab加folfox4或Folfiri在结肠直肠癌中，具有多种或不可切除的肝转移：A随机，第二期试验（Planet-TTD）
2. Randomized, Phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) Versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: The PRIME study [J] . DouillardJ.-Y., SienaS., CassidyJ., Journal of Clinical Oncology . 2010,第31期

机译：帕尼单抗与氟尿嘧啶，亚叶酸和奥沙利铂（FOLFOX4）输注的随机，III期试验与单独使用FOLFOX4作为先前未经治疗的转移性结直肠癌患者的一线治疗：PRIME研究
3. Randomised phase-II trial of CAPIRI (capecitabine, irinotecan) plus bevacizumab vs FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) plus bevacizumab as first-line treatment of patients with unresectable|[sol]|metastatic colorectal cancer (mCRC) [J] . J Souglakos, N Ziras, S Kakolyris, British Journal of Cancer . 2012,第3期

机译：CAPIRI（卡培他滨，伊立替康）加贝伐单抗与FOLFIRI（亚叶酸，5-氟尿嘧啶，伊立替康）加贝伐单抗的II期随机试验作为一线治疗不可切除的结肠癌（mCRC）患者
4. Electrocheiiiotherapy of Colorectal Liver Metastases-Trial Update [C] . I. Edhemovic, E. Brecelj, A. Ivanecz World Congress on Electroporation and Pulsed Electric Fields in Biology, Medicine and Food Environmental Technologies . 2016

机译：结直肠肝转移的电杂化 - 试验更新
5. Abnormal expression of proprotein convertases PC5/6 but not NARC-1 in human colorectal cancer and their liver metastases. [D] . Benay, Cassandre E. 2007

机译：在人类大肠癌及其肝转移中，前蛋白转化酶PC5 / 6而非NARC-1的异常表达。
6. Capecitabine plus Irinotecan (XELIRI regimen) compared to 5-FU/LV plus Irinotecan (FOLFIRI regimen) as neoadjuvant treatment for patients with unresectable liver-only metastases of metastatic colorectal cancer: a randomised prospective phase II trial [O] . Erik Skof, Martina Rebersek, Zvezdana Hlebanja, 2009

机译：卡培他滨加伊立替康（XELIRI方案）与5-FU / LV加伊立替康（FOLFIRI方案）比较用于新辅助治疗转移性结直肠癌不可切除的仅肝转移的患者：一项随机的前瞻性II期临床研究
7. Capecitabine plus Irinotecan (XELIRI regimen) compared to 5-FU/LV plus Irinotecan (FOLFIRI regimen) as neoadjuvant treatment for patients with unresectable liver-only metastases of metastatic colorectal cancer: a randomised prospective phase II trial [O] . Erik Skof, Martina Rebersek, Zvezdana Hlebanja, 2009

机译：卡培他滨加伊立替康（XELIRI方案）与5-FU / LV加伊立替康（FOLFIRI方案）比较用于新辅助治疗转移性结直肠癌不可切除的仅肝转移的患者：一项随机的前瞻性II期临床研究

First-line panitumumab plus FOLFOX4 or FOLFIRI in colorectal cancer with multiple or unresectable liver metastases: A randomised, phase II trial (PLANET-TTD)

摘要

著录项

引文网络

相似文献

相关主题

期刊订阅